Key result
Sacubitril/valsartan plus resveratrol boosts LVEF to ~70% vs. vehicle in post-MI rats.
Why the study?
Heart failure progression following myocardial infarction remains a major concern despite current therapies, prompting investigation into comparative and combinatorial benefits of resveratrol, sacubitril/valsartan, and valsartan.
Does the combination of resveratrol and sacubitril/valsartan improve cardiac remodeling and dysfunction in MI-induced rats compared to vehicle or monotherapy?
Does the combination of resveratrol and sacubitril/valsartan improve cardiac remodeling and dysfunction in MI-induced rats compared to vehicle or monotherapy?
Resveratrol and sacubitril/valsartan, alone or in combination, prevent cardiac remodeling and dysfunction in a rat model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for resveratrol with sacubitril/valsartan post-MI; leaves open translation to human remodeling trials.
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties. Sacubitril/valsartan is known to be beneficial in chronic HF patients. In this study, we investigated the comparative and combinatorial benefits of resveratrol with sacubitril/valsartan alongside an active comparator valsartan in MI-induced male Sprague Dawley rats. MI-induced and sham-operated animals received vehicle, resveratrol, sacubitril/valsartan, valsartan alone or sacubitril/valsartan + resveratrol for 8 weeks. Echocardiography was performed at the endpoint to assess cardiac structure and function. Cardiac oxidative stress, inflammation, fibrosis, brain natriuretic peptide (BNP), creatinine and neutrophil gelatinase associated lipocalin were measured. Treatment with resveratrol, sacubitril/valsartan, valsartan and sacubitril/valsartan + resveratrol significantly prevented left ventricular (LV) dilatation and improved LV ejection fraction in MI-induced rats. All treatments also significantly reduced myocardial tissue oxidative stress, inflammation and fibrosis, as well as BNP. Treatment with the combination of sacubitril/valsartan and resveratrol did not show additive effects. In conclusion, resveratrol, sacubitril/valsartan, and valsartan significantly prevented cardiac remodeling and dysfunction in MI-induced rats. The reduction in cardiac remodeling and dysfunction in MI-induced rats was mediated by a reduction in cardiac oxidative stress, inflammation and fibrosis.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2021) studied Myocardial infarction-induced heart failure. Sacubitril/valsartan and resveratrol vs. Vehicle (50% ethanol) was evaluated on Left ventricular ejection fraction (LVEF) at 8 weeks (p=<0.001). Treatment with the combination of sacubitril/valsartan and resveratrol significantly improved left ventricular ejection fraction and prevented dilatation in MI-induced rats compared to vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: